Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing